Morphine sulfate extended-release capsules for the treatment of chronic, moderate-to-severe pain

Bibliography

• Kuehn BM. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA 2007;297:249-51
   PubMed Web of Science ®Google Scholar
• Manchikanti L. Prescription drug abuse: what is being done to address this new drug epidemic? Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources. Pain Physician 2006;9:287-321
   Google Scholar
• Burgoyne DS. Prevalence and economic implications of chronic pain. Manag Care 2007;16(2 Suppl 3):2-4
   Google Scholar
• American Pain Society. Pain Control in the Primary Care Setting. Glenview, IL: American Pain Society; 2006;1-62
   Google Scholar
• Nagda J, Bajwa ZH. Definitions and classification of pain. In: Warfield CA, Bajwa ZH, editors, Principles and practice of pain medicine. New York: McGraw-Hill; 2004. p. 51-4
   Google Scholar
• Becker N, Bondegaard Thomsen A, Olsen AK, et al. Pain epidemiology and health related quality of life in chronic non-malignant pain patients referred to a Danish multidisciplinary pain center. Pain 1997;73:393-400
   PubMed Web of Science ®Google Scholar
• Marcus DA. Treatment of nonmalignant chronic pain. Am Fam Physician 2000;61:1331-46
   PubMed Web of Science ®Google Scholar
• Lipman AG, Jackson KC II. Opioid pharmacotherapy. In: Warfield CA, Bajwa ZH, editors, Principles and practices of pain medicine. New York: McGraw Hill; 2004. p. 583-600
   Google Scholar
• AGS Panel On Persistent Pain In Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc 2002;50:S205-24
   PubMed Web of Science ®Google Scholar
• McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther 2001;8:181-6
   PubMedGoogle Scholar
• Kalso E, Allan L, Dellemijn PL, et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 2003;7:381-6
   PubMed Web of Science ®Google Scholar
• Simon L, Lipman A, Jacox A, et al. Guideline for the management of arthritis pain in osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis. Glenview, IL: American Pain Society; 2002
   Google Scholar
• Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003;349:1943-53
   PubMed Web of Science ®Google Scholar
• Gagnon AM, Kahan M, Srivastava A. Opioid use and abuse: is there a problem? Clin J Pain 2007;23:661-2
   PubMed Web of Science ®Google Scholar
• Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112:372-80
   PubMed Web of Science ®Google Scholar
• Manchikanti L. National drug control policy and prescription drug abuse: facts and fallacies. Pain Physician 2007;10:399-424
   PubMedGoogle Scholar
• Trescot AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006;9:1
   PubMedGoogle Scholar
• Dickinson BD, Altman RD, Nielsen NH, Williams MA. Use of opioids to treat chronic, noncancer pain. West J Med 2000;172:107-15
   PubMedGoogle Scholar
• Gourlay GK. Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine. Clin Pharmacokinet 1998;35:173-90
   PubMed Web of Science ®Google Scholar
• Kadian (package insert), Piscataway NJ. Alpharma Pharmaceuticals LLC; 2007
   Google Scholar
• Gourlay GK, Cherry DA, Onley MM, et al. Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain. Pain 1997;69:295-302
   PubMed Web of Science ®Google Scholar
• Alpharma Pharmaceuticals LLC. KADIAN® (Morphine Sulfate Extended-release Capsules) Polymer-coated Shell Technology; 2004. Available from: www.kadian.com
   Google Scholar
• Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 1999;86:1856-66
   PubMed Web of Science ®Google Scholar
• Maccarrone C, West RJ, Broomhead AF, Hodsman GP. Single dose pharmacokinetics of Kapanol™, a new oral sustained-release morphine formulation. Drug Invest 1994;7:262-74
   Google Scholar
• MS Contin (package insert), Stamford CT. Purdue Pharma LP; 2007
   Google Scholar
• MXL SPC (package insert), Cambridge, UK, Napp Pharmaceuticals Ltd; 2007
   Google Scholar
• Broomhead A, West R, Eglinton L, et al. Comparative single-dose pharmacokinetics of sustained-release and modified-release morphine sulfate capsules under fed and fasting conditions. Clin Drug Invest 1997;13:162-70
   Web of Science ®Google Scholar
• Avinza (package insert). Bristol, TN: King Pharmaceuticals, Inc.; 2006
   Google Scholar
• US Food And Drug Administration, Center for drug evaluation and research. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products – general considerations; 2007
   Google Scholar
• Royal M. A head-to-head, single-dose trial of KADIAN® vs AVINZA® 30 mg in healthy, opioid-naïve subjects in the fed state: comparison of pharmacokinetics. J Pain 2005;6(3):S41
   PubMed Web of Science ®Google Scholar
• Nicholson B, Ross E, Weil A, et al. Treatment of chronic moderate-to-severe non-malignant pain with polymer-coated extended-release morphine sulfate capsules. Curr Med Res Opin 2006;22:539-50
   PubMed Web of Science ®Google Scholar
• Jones R, Hale E, Talomsin L, Phillips R. Kapanol capsules: pellet formulation provides alternative methods of administration of sustained-release morphine sulfate. Clin Drug Invest 1996;12:88-93
   PubMed Web of Science ®Google Scholar
• Broomhead A, West R, Kadirgamanathan G, et al. Comparative bioavailability of sustained-release morphine sulfate capsules versus pellets. Clin Drug Invest 1997;14:137-45
   Web of Science ®Google Scholar
• Semenchuk MR. Avinza Elan. Curr Opin Invest Drugs 2002;3:1369-72
   PubMedGoogle Scholar
• King CR. AVINZA (morphine sulfate extended-release capsules). Clin J Oncol Nurs 2003;7:458-78
   PubMedGoogle Scholar
• US Food And Drug Administration. FDA alert: alcohol-palladone interaction. Alert for healthcare professionals: hydromorphone hydrochloride extended-release capsules. Available from: http://www.fda.gov/cder/drug/InfoSheets/HCP/hydromorphoneHCP.htm
   Google Scholar
• Opana ER (package insert). Chadds Ford, PA: Endo Pharmaceuticals, Inc.; 2007
   Google Scholar
• Johnson F, Wagner G, Sun S, Stauffer J. Effect of concomitant ingestion of alcohol on the in vivo pharmacokinetics of KADIAN (morphine sulfate extended-release) capsules. J Pain 2008;9(4):330-6
   PubMedGoogle Scholar
• Kerr RO, Tester WJ. A patient preference study comparing two extended-release morphine sulfate formulations (once-daily KADIAN® versus twice-daily MS Contin®) for cancer pain. Clin Drug Invest 2000;19:25-32
   Web of Science ®Google Scholar
• Broomhead A, Kerr R, Tester W, et al. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. J Pain Symptom Manage 1997;14:63-73
   PubMed Web of Science ®Google Scholar
• Flöter T, Koch EMW; KAP-CAS Study Group. Comparison of two oral morphine formulations for chronic severe pain of malignant and nonmalignant origin Kapanol™ vs MST®. Clin Drug Invest 1997;14:183-91
   Web of Science ®Google Scholar
• Farrar JT, Young JP Jr, Lamoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58
   PubMed Web of Science ®Google Scholar
• Ware JE Jr. SF-36 health survey update. Spine 2000;25:3130-9
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Kosinski M, Dewey JE. How to score version 2 of the SF-36 ® Health Survey. Lincoln, RI: QualityMetric Incorporated; 2000
   Google Scholar
• Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001;19:2542-54
   PubMed Web of Science ®Google Scholar
• Quang-Cantagrel ND, Wallace MS, Magnuson SK. Opioid substitution to improve effectiveness of chronic non cancer pain control: a chart review. Anesth Analg 2000;90:933-7
   PubMed Web of Science ®Google Scholar
• Quigley C. Opioid switching to improve pain relief and drug tolerability [review]. Cochrane Database Syst Rev 2007;(4):1-28
   Google Scholar
• Thomsen AB, Becker N, Eriksen J. Opioid rotation in chronic non-malignant pain patients: a retrospective study. Acta Anaesthesiol Scand 1999;43:918-23
   PubMed Web of Science ®Google Scholar
• Sasaki J, Weil A, Ross E, Nicholson B. Effectiveness of polymer-coated extended-release morphine sulfate capsules in older patients with persistent moderate-to-severe pain: a subgroup analysis of a large, open-label, community-based trial. Curr Ther Res Clin Exp 2007;68:137-50
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacological management of neuropathic pain: evidence-based recommendations. Pain 2008;132:237-51
   Web of Science ®Google Scholar
• Galluzzi K. Managing neuropathic pain. J Am Osteopath Assoc 2007;107:ES39-48
   PubMedGoogle Scholar
• Nicholson B, Sasaki J, Weil A, Ross E. Treatment of neuropathic pain with KADIAN® in poor responders to other pain medications. J Pain 2005;6(3):S44
   Google Scholar
• Weil A, Sasaki J, Ross E, Nicholson B. Factors impacting KADIAN® once- or twice-daily dosing regimens: analysis from the KRONUS-MSP Trial. J Pain 2005;6(3):S43
   Google Scholar
• Nicholson B, Ross E, Sasaki J, Weil A. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. Curr Med Res Opin 2006;22:1503-14
   PubMed Web of Science ®Google Scholar
• Adams D, Gunyea I, Bhakta B, et al. Retrospective assessment of frequency of dosing of sustained release opiate preparations in chronic pain patients. Pain Med 2002;3:185
   Google Scholar
• Marcus DA, Glick RM. Sustained-release oxycodone dosing survey of chronic pain patients. Clin J Pain 2004;20:363-6
   PubMed Web of Science ®Google Scholar
• Chao J. Retrospective analysis of Kadian® (morphine sulfate sustained-release capsules) in patients with chronic, nonmalignant pain. Pain Med 2005;6:262-5
   PubMed Web of Science ®Google Scholar
• Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA 2000;283:1710-4
   PubMed Web of Science ®Google Scholar
• Katz NP, Adams EH, Benneyan JC, et al. Foundations of opioid risk management. Clin J Pain 2007;23:103-18
   PubMed Web of Science ®Google Scholar
• Sloan P, Babul N. Extended-release opioids for the management of chronic non-malignant pain. Expert Opin Drug Deliv 2006;3:489-97
   PubMedGoogle Scholar
• Butler SF, Venuti SW, Benoit C, et al. Internet surveillance: content analysis and monitoring of product-specific Internet prescription opioid abuse-related postings. Clin J Pain 2007;23:619-28
   PubMed Web of Science ®Google Scholar
• Butler SF, Benoit CB, Simon H, et al. Development and validation of an opioid attractiveness scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J 2006;3:5
   PubMedGoogle Scholar
• Office Of National Drug Control Policy. The president's national drug control strategy. Healing America's drug users: getting treatment resources where they are needed. 2004. Available from: http://www.whitehousedrugpolicy.gov/publications/policy/ndcs04/healing_amer.html
   Google Scholar
• Zacny J, Bigelow G, Compton P, et al. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 2003;69:215-32
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Results from the 2003 National Survey on Drug Use and Health: National Findings. Rockville MD, SAMHSA; 2004
   Google Scholar
• Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003;63:17-32
   PubMed Web of Science ®Google Scholar
• D'honneur G, Sandouk P, Scherrmann JM, Duvaldestin P. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. Anesthesiology 1994;81:87-93
   PubMed Web of Science ®Google Scholar
• Budd K. Pain management: is opioid immunosuppression a clinical problem? Biomed Pharmacother 2006;60:310-7
   PubMed Web of Science ®Google Scholar
• Page GG. Immunologic effects of opioids in the presence or absence of pain. J Pain Symptom Manage 2005;29:S25-31
   Web of Science ®Google Scholar
• Gallagher RM, Welz-Bosna M, Gammaitoni A. Assessment of dosing frequency of sustained-release opioid preparations in patients with chronic nonmalignant pain. Pain Med 2007;8:71-4
   PubMed Web of Science ®Google Scholar